{"id":"NCT05523895","sponsor":"ACADIA Pharmaceuticals Inc.","briefTitle":"Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder","officialTitle":"A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2022-08-09","primaryCompletion":"2024-09-27","completion":"2024-09-27","firstPosted":"2022-08-31","resultsPosted":"2025-08-24","lastUpdate":"2025-08-24"},"enrollment":237,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Irritability Associated With Autism Spectrum Disorder"],"interventions":[{"type":"DRUG","name":"Pimavanserin","otherNames":["Nuplazid"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Pimavanserin low dose","type":"EXPERIMENTAL"},{"label":"Pimavanserin high dose","type":"EXPERIMENTAL"}],"summary":"6-week, randomized, double-blind, fixed-dose, placebo-controlled, parallel group study in children and adolescents (aged 5 to17 years) with autism spectrum disorder (ASD) with irritability, agitation, or self-injurious behaviors to study the efficacy and safety of pimavanserin","primaryOutcome":{"measure":"Change From Baseline at Week 6 in Caregiver-rated Aberrant Behavior Checklist Irritability (ABC-I) Subscale Score","timeFrame":"6 weeks","effectByArm":[{"arm":"Placebo","deltaMin":-9.6,"sd":1.06},{"arm":"Pimavanserin Low Dose","deltaMin":-11.2,"sd":1.09},{"arm":"Pimavanserin High Dose","deltaMin":-11.2,"sd":1.05}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2986"},{"comp":"OG000 vs OG002","p":"0.2859"}]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":21},"locations":{"siteCount":57,"countries":["United States","Australia","France","Hungary","Italy","Poland","Serbia","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":78},"commonTop":["Upper respiratory tract infection","Headache","Somnolence","Nausea","Decreased appetite"]}}